So-Called Serous Carcinoma of the Uterine Cervix with < b > < i > BRCA2 < /i > < /b > Mutation: Case Report and Review of the Literature

We describe the case of a patient with a carcinoma categorized as stage IVB SCUC, initially treated with carboplatin, paclitaxel, and bevacizumab, followed by maintenance with bevacizumab. After locoregional progression, radiotherapy was administered. Unfortunately, further progression was observed, and carboplatin was resumed. Considering the presence of aBRCA2 mutation as detected by NGS, treatment with a PARP inhibitor (olaparib) was decided and allowed disease control for 6 months. We believe thatBRCA mutation may be systematically searched in patients suffering from carcinomas formerly referred to as SCUC and that targeted treatments should be considered.Case Rep Oncol 2021;14:1792 –1798
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research